Nurix Therapeutics
NRIX
68 hedge funds and large institutions have $1.09B invested in Nurix Therapeutics in 2020 Q4 according to their latest regulatory filings, with 15 funds opening new positions, 27 increasing their positions, 12 reducing their positions, and 12 closing their positions.
125% more repeat investments, than reductions
Existing positions increased: 27 | Existing positions reduced: 12
50% more funds holding in top 10
Funds holding in top 10: 4 → 6 (+2)
25% more first-time investments, than exits
New positions opened: 15 | Existing positions closed: 12
3% more funds holding
Funds holding: 66 → 68 (+2)
0.72% less ownership
Funds ownership: 86% → 85.28% (-0.72%)
2% less capital invested
Capital invested by funds: $1.11B → $1.09B (-$21.9M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
+$18.3M |
| 2 |
BlackRock
New York
|
+$16.6M |
| 3 |
EC
EcoR1 Capital
San Francisco,
California
|
+$11.7M |
| 4 |
State Street
Boston,
Massachusetts
|
+$10.6M |
| 5 |
RG
Redmile Group
San Francisco,
California
|
+$8.37M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
-$30.5M |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$7.82M |
| 3 |
BC
Boxer Capital
San Diego,
California
|
-$4.29M |
| 4 |
Ameriprise
Minneapolis,
Minnesota
|
-$4.19M |
| 5 |
WMSA
Weiss Multi-Strategy Advisers
New York
|
-$1.8M |
NRIX Hedge Fund Activity: Q4 2020 in Review
68 of the 5,651 institutional investors tracked by Wall St. Rank reported a position in Nurix Therapeutics (NRIX) for Q4 2020, worth a combined $1.09B — down 2% from $1.11B a quarter earlier.
Buyers outnumbered sellers: 15 funds opened new NRIX positions and 12 closed out — a net gain of 3 holders — while 27 added to existing stakes and 12 trimmed.
The largest buyer was Eventide Asset Management, adding an estimated $18.3M. The largest seller was Wellington Management Group, cutting an estimated $30.5M.
- 68 institutional investors held Nurix Therapeutics (NRIX) as of Q4 2020, up from 66 in Q3 2020.
- Funds reported $1.09B of Nurix Therapeutics stock for Q4 2020, down 2% quarter-over-quarter.
- 15 funds opened new Nurix Therapeutics positions in Q4 2020 and 12 closed out, a net change of +3 holders.
- The largest Nurix Therapeutics buyer in Q4 2020 was Eventide Asset Management, an estimated $18.3M added.
- The largest Nurix Therapeutics seller in Q4 2020 was Wellington Management Group, an estimated $30.5M sold.
Based on aggregated 13F filings for Q4 2020.